If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"KIVEXA PMS","allocation":"","arm_groups":[{"arm_group_label":"abacavir/lamivudine","arm_group_description":"The subjects with Human Immunodeficiency Virus infection","arm_type":""}],"assignment":"","brief_summary":"This is an open label, multi-centre, non-interventional post-marketing surveillance.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of KIVEXA(abacavir/lamivudine) administered in Korean patients according to the prescribing information","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"03/04/2020 17:05:55","criteria":"Inclusion Criteria:\nAll subjects must satisfy the following criteria at study entry:\n1)Subjects with no experience of treatment using abacavir/lamivudine\n2)Subjects administrated abacavir/lamivudine in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age\n3)Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen\n4)Subjects administrated abacavir/lamivud following the locally approved prescribing information\n\n\nExclusion Criteria:\nConsidering the nature of this non-interventional post-marketing surveillance study, there is no strict exclusion criteria set up. The doctors participating this study to enrol the subjects prescribed with abacavir/lamivudine following the locally approved prescribing information.\nThe following criteria should be checked at the time of study entry.\nAccording to contraindication on the prescribing information, abacavir/lamivudin should not be administrated to the following patients:\n1)Subjects with hypersensitivity to the active substances or to any of the excipients\n2)Subjects with moderate or severe hepatic impairment\n3)Subject with end-stage renal disease \n4)Subject with ≤40kg in weight\n5)Subject with creatinine clearance <50ml/min\n\n -","detailed_description":"This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of abacavir/lamivudine administered in Korean patients according to the prescribing information.","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"N/A","display_phase_internal":"PHASE_NA","display_status":"Finalized","display_status_internal":"RECSTATUS_O_COMPLETED","endpoint":"","enrollment":"154","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"","id":"adbb98f6-c825-5ec5-a2a4-9edff6ba3653","internal":{"content":null,"contentDigest":"e528f02830749f49d07b241e44083553","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\nAll subjects must satisfy the following criteria at study entry:\n1)Subjects with no experience of treatment using abacavir/lamivudine\n2)Subjects administrated abacavir/lamivudine in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age\n3)Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen\n4)Subjects administrated abacavir/lamivud following the locally approved prescribing information\n\n\nExclusion Criteria:\nConsidering the nature of this non-interventional post-marketing surveillance study, there is no strict exclusion criteria set up. The doctors participating this study to enrol the subjects prescribed with abacavir/lamivudine following the locally approved prescribing information.\nThe following criteria should be checked at the time of study entry.\nAccording to contraindication on the prescribing information, abacavir/lamivudin should not be administrated to the following patients:\n1)Subjects with hypersensitivity to the active substances or to any of the excipients\n2)Subjects with moderate or severe hepatic impairment\n3)Subject with end-stage renal disease \n4)Subject with ≤40kg in weight\n5)Subject with creatinine clearance <50ml/min\n\n -","interventions":[{"arm_group_label":"abacavir/lamivudine","intervention_description":"Basically there is no treatment allocation. Subjects who would be administrated of abacavir/lamivudine at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.","intervention_name":"abacavir/lamivudine","intervention_type":"drug"}],"interventional_subtype":"","is_fda_regulated":false,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"04/30/2018 00:00:00","links":[],"locations":[{"City":"Daegu","Latitude":"35.8714354","CountryDisplay":"South Korea","Longitude":"128.601445","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":"12","minimum_age_raw":"12 Years","modified_date":"03/04/2020 17:05:55","number_of_arms":"0","observational_design":{"biospecimen_description":"","biospecimen_retention":"None Retained","number_of_groups":"1","observational_study_design":"Other","patient_registry":"false","target_duration_quantity":"","target_duration_units":"","timing":"Prospective"},"official_title":"An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of KIVEXA(abacavir/lamivudine) administered in Korean patients according to the prescribing information","org_study_id":"116287","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Observational","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":["Korea: MFDS(Ministry of Food and Drug Safety)"]},"phase":"N/A","primary_compl_date":"04/30/2018 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"The number of adverse event after abacavir/lamivudine administration","outcome_time_frame":"12 months","outcome_safety_issue":null}],"product_name":"abacavir;abacavir/lamivudine;lamivudine","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"The number of unexpected adverse event after abacavir/lamivudine administration","outcome_time_frame":"12 months","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"The number of serious adverse event after abacavir/lamivudine administration","outcome_time_frame":"12 months","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["N/A"]},"start_date":"03/15/2013 00:00:00","study_type":"Observational","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"116287"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}